» Articles » PMID: 36668840

Prediction Model for Identifying Computational Phenotypes of Children with Cerebral Palsy Needing Neurotoxin Treatments

Overview
Journal Toxins (Basel)
Publisher MDPI
Specialty Toxicology
Date 2023 Jan 20
PMID 36668840
Authors
Affiliations
Soon will be listed here.
Abstract

Factors associated with neurotoxin treatments in children with cerebral palsy (CP) are poorly studied. We developed and externally validated a prediction model to identify the prognostic phenotype of children with CP who require neurotoxin injections. We conducted a longitudinal, international, multicenter, double-blind descriptive study of 165 children with CP (mean age 16.5 ± 1.2 years, range 12−18 years) with and without neurotoxin treatments. We collected functional and clinical data from 2005 to 2020, entered them into the BTX-PredictMed machine-learning model, and followed the guidelines, “Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis”. In the univariate analysis, neuromuscular scoliosis (p = 0.0014), equines foot (p < 0.001) and type of etiology (prenatal > peri/postnatal causes, p = 0.05) were linked with neurotoxin treatments. In the multivariate analysis, upper limbs (p < 0.001) and trunk muscle tone disorders (p = 0.02), the presence of spasticity (p = 0.01), dystonia (p = 0.004), and hip dysplasia (p = 0.005) were strongly associated with neurotoxin injections; and the average accuracy, sensitivity, and specificity was 75%. These results have helped us identify, with good accuracy, the clinical features of prognostic phenotypes of subjects likely to require neurotoxin injections.

Citing Articles

A Systematic Review of Botulinum Toxin Injection in Pediatric Dystonia.

Rasera A, Squintani G, Cerruto M Toxins (Basel). 2024; 16(7.

PMID: 39057929 PMC: 11281719. DOI: 10.3390/toxins16070289.


Introduction to the Special Issue on Botulinum Toxins: New Uses in the Treatment of Diseases.

Luvisetto S Toxins (Basel). 2023; 15(9).

PMID: 37755966 PMC: 10535787. DOI: 10.3390/toxins15090540.

References
1.
Bertoncelli C, Altamura P, Vieira E, Bertoncelli D, Solla F . Using Artificial Intelligence to Identify Factors Associated with Autism Spectrum Disorder in Adolescents with Cerebral Palsy. Neuropediatrics. 2019; 50(3):178-187. DOI: 10.1055/s-0039-1685525. View

2.
Biering-Soerensen B, Stevenson V, Bensmail D, Grabljevec K, Martinez Moreno M, Pucks-Faes E . European expert consensus on improving patient selection for the management of disabling spasticity with intrathecal baclofen and/or botulinum toxin type A. J Rehabil Med. 2021; 54:jrm00241. PMC: 8862646. DOI: 10.2340/16501977-2877. View

3.
Corry I, Cosgrove A, Duffy C, McNeill S, Taylor T, Graham H . Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial. J Pediatr Orthop. 1998; 18(3):304-11. View

4.
Solla F, Tran A, Bertoncelli D, Musoff C, Bertoncelli C . Why a P-Value is Not Enough. Clin Spine Surg. 2018; 31(9):385-388. DOI: 10.1097/BSD.0000000000000695. View

5.
Lasko T, Denny J, Levy M . Computational phenotype discovery using unsupervised feature learning over noisy, sparse, and irregular clinical data. PLoS One. 2013; 8(6):e66341. PMC: 3691199. DOI: 10.1371/journal.pone.0066341. View